Associated Papers
TP53 mutation heterogeneity reveals distinct prognoses in mantle cell lymphoma.
Liu S et al.
Annals of Hematology, 2026
Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.
Allsopp RC et al.
Bmc Cancer, 2025
High-throughput evaluation of genetic variants with prime editing sensor libraries.
Gould SI et al.
Nature Biotechnology, 2025
Scalable approaches for generating, validating and incorporating data from high-throughput functional assays to improve clinical variant classification.
Padigepati SR et al.
Human Genetics, 2024
Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations.
Tang Y et al.
Cell Reports, 2022
Analysis and Interpretation of the Impact of Missense Variants in Cancer.
Petrosino M et al.
International Journal of Molecular Sciences, 2021
NMR spectroscopy uncovers direct interaction between BAF60A and p53.
Han J et al.
Biochemical and Biophysical Research Communications, 2021
Comprehensive Study of Germline Mutations and Double-Hit Events in Esophageal Squamous Cell Cancer.
Zeng B et al.
Frontiers in Oncology, 2021
p53 tetramerization: at the center of the dominant-negative effect of mutant p53.
Gencel-Augusto J et al.
Genes & Development, 2020
The cancer-associated, gain-of-function TP53 variant P152Lp53 activates multiple signaling pathways implicated in tumorigenesis.
Singh S et al.
The Journal of Biological Chemistry, 2019
Finding driver mutations in cancer: Elucidating the role of background mutational processes.
Brown AL et al.
Plos Computational Biology, 2019
Machine Learning Classification and Structure-Functional Analysis of Cancer Mutations Reveal Unique Dynamic and Network Signatures of Driver Sites in Oncogenes and Tumor Suppressor Genes.
Agajanian S et al.
Journal of Chemical Information and Modeling, 2018
Tetramer formation of tumor suppressor protein p53: Structure, function, and applications.
Kamada R et al.
Biopolymers, 2016
Structure-Based Analysis Reveals Cancer Missense Mutations Target Protein Interaction Interfaces.
Engin HB et al.
Plos One, 2016
TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution.
Hou HA et al.
Blood Cancer Journal, 2015
Reproducible Analysis of Post-Translational Modifications in Proteomes--Application to Human Mutations.
Holehouse AS et al.
Plos One, 2015
TP53 mutations in human cancer: database reassessment and prospects for the next decade.
Leroy B et al.
Human Mutation, 2014
Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.
Van Allen EM et al.
Nature Medicine, 2014
Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.
Kamada R et al.
The Journal of Biological Chemistry, 2011
Cellular adaptation to hypoxia and p53 transcription regulation.
Zhao Y et al.
Journal of Zhejiang University. Science. B, 2009
Evaluation of transcriptional activity of p53 in individual living mammalian cells.
Imagawa T et al.
Analytical Biochemistry, 2009
Noncanonical DNA motifs as transactivation targets by wild type and mutant p53.
Jordan JJ et al.
Plos Genetics, 2008
Parallel analysis of tetramerization domain mutants of the human p53 protein using PCR colonies.
Merritt J et al.
Genomic Medicine, 2007
Kinetic computational alanine scanning: application to p53 oligomerization.
Chong LT et al.
Journal of Molecular Biology, 2006
Unfolding, aggregation, and amyloid formation by the tetramerization domain from mutant p53 associated with lung cancer.
Higashimoto Y et al.
Biochemistry, 2006
The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library.
Kawaguchi T et al.
Oncogene, 2005
Structure and functionality of a designed p53 dimer.
Davison TS et al.
Journal of Molecular Biology, 2001
p53 functional assays: detecting p53 mutations in both the germline and in sporadic tumours.
Camplejohn RS et al.
Cell Proliferation, 2001
Cellular characterisation of p53 mutants with a single missense mutation in the beta-strand 326-333 and correlation of their cellular activities with in vitro properties.
Chène P et al.
Journal of Molecular Biology, 1999
Characterization of p53 mutants identified in human tumors with a missense mutation in the tetramerization domain.
Rollenhagen C et al.
International Journal of Cancer, 1998
Nine hydrophobic side chains are key determinants of the thermodynamic stability and oligomerization status of tumour suppressor p53 tetramerization domain.
Mateu MG et al.
The Embo Journal, 1998
TP53 lacks tetramerization and N-terminal domains due to novel inactivating mutations detected in leukemia patients.
Hameed Y et al.
Journal of Cancer Research and Therapeutics, 0